标题: Anna S. Lok，密西根大学——HBV相关实验室及人物介绍系列 [打印本页] 作者: bigben446 时间: 2016-5-10 23:11 标题: Anna S. Lok，密西根大学——HBV相关实验室及人物介绍系列
Anna S. Lok，密西根大学——HBV相关实验室及人物介绍系列
Anna S. Lok，密西根大学
Lok, A. S. and B. J. McMahon, et al. (2016). "Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis." Hepatology 63(1): 284-306.
Jonas, M. M. and A. S. Lok, et al. (2016). "Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis." Hepatology 63(1): 307-18.
Brown, R. J. and B. J. McMahon, et al. (2016). "Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis." Hepatology 63(1): 319-33.
Patel, A. and S. Yapali, et al. (2016). "Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014." Hepatol Int 10(1): 139-46.
Park, J. J. and D. K. Wong, et al. (2016). "Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B." Gastroenterology 150(3): 684-695.e5.
Thomson, M. and M. A. Konerman, et al. (2016). "Primary Care Physician Perspectives on Hepatitis C Management in the Era of Direct-Acting Antiviral Therapy." Dig Dis Sci.
Khalili, M. and M. Lombardero, et al. (2015). "Diabetes and prediabetes in patients with hepatitis B residing in North America." Hepatology 62(5): 1364-74.
Liang, T. J. and T. M. Block, et al. (2015). "Present and future therapies of hepatitis B: From discovery to cure." Hepatology 62(6): 1893-908.
Lok, A. S. (2015). "Personalized treatment of hepatitis B." Clin Mol Hepatol 21(1): 1-6.
Perrillo, R. P. and P. Martin, et al. (2015). "Preventing hepatitis B reactivation due to immunosuppressive drug treatments." JAMA 313(16): 1617-8.
Wu, E. and X. Chen, et al. (2015). "A comparative study of patients' knowledge about hepatitis C in the United States and in urban and rural China." Hepatol Int 9(1): 58-66.
Konerman, M. A. and Y. Zhang, et al. (2015). "Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data." Hepatology 61(6): 1832-41.
Di Bisceglie, A. M. and A. S. Lok, et al. (2015). "Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?" Hepatology 61(2): 703-11.
Konerman, M. A. and A. S. Lok (2015). "Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy?" Clin Gastroenterol Hepatol 13(2): 386-9.
Yapali, S. and N. Talaat, et al. (2015). "Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation." Clin Gastroenterol Hepatol 13(1): 193-201.e1.
Dan, Y. Y. and J. B. Wong, et al. (2014). "Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries." Hepatol Int 8(3): 382-94.
Konerman, M. A. and A. S. Lok (2014). "Diagnostic challenges of hepatitis C." JAMA 311(24): 2536-7.
Terrault, N. A. and R. T. Stravitz, et al. (2014). "Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study." Hepatology 59(4): 1311-9.
Wei, L. and A. S. Lok (2014). "Impact of new hepatitis C treatments in different regions of the world." Gastroenterology 146(5): 1145-50.e1-4.
Hwang, J. P. and M. E. Suarez-Almazor, et al. (2014). "Hepatitis C virus screening in patients with cancer receiving chemotherapy." J Oncol Pract 10(3): e167-74.
Lok, A. S. and D. F. Gardiner, et al. (2014). "Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders." J Hepatol 60(3): 490-9.
Yapali, S. and N. Talaat, et al. (2014). "Management of hepatitis B: our practice and how it relates to the guidelines." Clin Gastroenterol Hepatol 12(1): 16-26.
Sharma, P. and A. Hosmer, et al. (2013). "Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival." Hepatol Int 7(4): 990-9.
Chu, D. and J. D. Yang, et al. (2013). "Hepatitis B screening and vaccination practices in asian american primary care." Gut Liver 7(4): 450-7.
Yapali, S. and A. S. Lok (2013). "Should treatment of hepatitis B patients be based solely on liver fibrosis?" Clin Gastroenterol Hepatol 11(11): 1500-2.
Kanwal, F. and A. S. Lok, et al. (2013). "CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages." Clin Gastroenterol Hepatol 11(3): 200-3.
Kanwal, F. and A. S. Lok, et al. (2013). "CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages." Gastroenterology 144(3): 478-81.
Kwei, K. and X. Tang, et al. (2013). "Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation." J Virol 87(4): 2352-7.
Everson, G. T. and N. A. Terrault, et al. (2013). "A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation." Hepatology 57(5): 1752-62.
Morishima, C. and M. L. Shiffman, et al. (2012). "Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C." Am J Gastroenterol 107(9): 1388-98.
Lok, A. S. and H. Trinh, et al. (2012). "Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B." Gastroenterology 143(3): 619-28.e1.
Lok, A. S. and J. W. Ward, et al. (2012). "Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable." Ann Intern Med 156(10): 743-5.
Scaglione, S. J. and A. S. Lok (2012). "Effectiveness of hepatitis B treatment in clinical practice." Gastroenterology 142(6): 1360-1368.e1.
Lok, A. S. and J. M. Pawlotsky (2012). "Viral hepatitis at a crossroad." Gastroenterology 142(6): 1261-3.
Lok, A. S. and D. F. Gardiner, et al. (2012). "Preliminary study of two antiviral agents for hepatitis C genotype 1." N Engl J Med 366(3): 216-24.
Ward, J. W. and A. S. Lok, et al. (2012). "Report on a single-topic conference on "Chronic viral hepatitis--strategies to improve effectiveness of screening and treatment"." Hepatology 55(1): 307-15.
Fontana, R. J. and H. J. Litman, et al. (2012). "YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C." Liver Int 32(4): 665-74.
Dao, D. Y. and L. S. Hynan, et al. (2012). "Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels." Hepatology 55(3): 676-84.
Sterling, R. K. and E. C. Wright, et al. (2012). "Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C." Am J Gastroenterol 107(1): 64-74.
Lok, A. S. (2012). "Does antiviral therapy prevent recurrence of hepatitis B virus-related hepatocellular carcinoma after curative liver resection?" JAMA 308(18): 1922-24.
Ghany, M. G. and H. Y. Kim, et al. (2011). "Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial." Hepatology 54(5): 1527-37.
Sharma, P. and A. S. Lok (2011). "Interferon-free treatment regimens for hepatitis C: are we there yet?" Gastroenterology 141(6): 1963-7.
Curto, T. M. and R. J. Lagier, et al. (2011). "Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7)." Pharmacogenet Genomics 21(12): 851-60.
Rakoski, M. O. and M. B. Brown, et al. (2011). "Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C." Clin Gastroenterol Hepatol 9(10): 902-909.e1.
O'Brien, T. R. and J. E. Everhart, et al. (2011). "An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C." PLoS One 6(7): e20904.
Huang, Y. and S. Tong, et al. (2011). "Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21." Gastroenterology 141(4): 1412-21, 1421.e1-5.
Hongthanakorn, C. and W. Chotiyaputta, et al. (2011). "Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice." Hepatology 53(6): 1854-63.
Dienstag, J. L. and M. G. Ghany, et al. (2011). "A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C." Hepatology 54(2): 396-405.
Kwon, H. and A. S. Lok (2011). "Hepatitis B therapy." Nat Rev Gastroenterol Hepatol 8(5): 275-84.
Lok, A. S. and J. E. Everhart, et al. (2011). "Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C." Hepatology 54(2): 434-42.
Lok, A. S. and J. E. Everhart, et al. (2011). "Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C." Gastroenterology 140(3): 840-9; quiz e12.
Kronfol, Z. and H. J. Litman, et al. (2011). "No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C." J Affect Disord 129(1-3): 205-12.
Chotiyaputta, W. and C. Peterson, et al. (2011). "Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B." J Hepatol 54(1): 12-8.
Lok, A. S. and W. R. Kim, et al. (2010). "Overview of the viral hepatitis problem." J Fam Pract 59(4 Suppl): S11-6.
Lee, J. and A. S. Lok, et al. (2010). "Hepatitis B prevalence among Asian Americans in Michigan: an assessment to guide future education and intervention strategies." J Community Health 35(5): 534-42.
El-Serag, H. and A. S. Lok, et al. (2010). "The dawn of a new era: transforming our domestic response to hepatitis B & C." Gastroenterology 138(4): 1225-30, 1230.e1-3.
Lok, A. S. (2010). "Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase?" Hepatology 51(4): 1107-9.
Delgado-Borrego, A. and S. H. Jordan, et al. (2010). "Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial." Clin Gastroenterol Hepatol 8(5): 458-62.
Ghany, M. G. and A. S. Lok, et al. (2010). "Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C." Gastroenterology 138(1): 136-46.
Brunetto, M. R. and A. S. Lok (2010). "New approaches to optimize treatment responses in chronic hepatitis B." Antivir Ther 15 Suppl 3: 61-8.
Hongthanakorn, C. and A. S. Lok (2010). "New pharmacologic therapies in chronic hepatitis B." Gastroenterol Clin North Am 39(3): 659-80.
Fontana, R. J. and J. L. Dienstag, et al. (2010). "Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C." Gut 59(10): 1401-9.
Pockros, P. J. and F. M. Hamzeh, et al. (2010). "Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments." Hepatology 52(4): 1193-200.
Morgan, T. R. and M. G. Ghany, et al. (2010). "Outcome of sustained virological responders with histologically advanced chronic hepatitis C." Hepatology 52(3): 833-44.
Volk, M. L. and R. Tocco, et al. (2009). "Public health impact of antiviral therapy for hepatitis C in the United States." Hepatology 50(6): 1750-5.
Bzowej, N. and S. Han, et al. (2009). "Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B." Liver Transpl 15(9): 1010-20.
Lok, A. S. and B. J. McMahon (2009). "Chronic hepatitis B: update 2009." Hepatology 50(3): 661-2.
Freedman, N. D. and J. E. Everhart, et al. (2009). "Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C." Hepatology 50(5): 1360-9.
Fleischer, R. D. and A. S. Lok (2009). "Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B." J Hepatol 51(4): 787-91.
Chotiyaputta, W. and A. S. Lok (2009). "Hepatitis B virus variants." Nat Rev Gastroenterol Hepatol 6(8): 453-62.
Everhart, J. E. and A. S. Lok, et al. (2009). "Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial." Gastroenterology 137(2): 549-57.
Lok, A. S. (2009). "Evolution of nucleoside/tide analogues for hepatitis B: is the ideal drug here yet?" J Hepatol 51(2): 416-8.
Afdhal, N. H. and A. S. Lok, et al. (2009). "Clinical decisions. Management of incidental hepatitis C virus infection." N Engl J Med 360(18): 1902-6.
Degertekin, B. and A. S. Lok (2009). "Indications for therapy in hepatitis B." Hepatology 49(5 Suppl): S129-37.
Degertekin, B. and A. S. Lok (2009). "Update on viral hepatitis: 2008." Curr Opin Gastroenterol 25(3): 180-5.
Lok, A. S. and J. E. Everhart, et al. (2009). "Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial." Hepatology 49(6): 1828-37.
Degertekin, B. and A. S. Lok (2009). "Do guidelines preclude hepatitis B patients from receiving treatment?" Hepatology 49(2): 700-1; author reply 701-2.
Degertekin, B. and A. S. Lok (2009). "What is the optimal regimen for preventing hepatitis B recurrence after liver transplantation?" Nat Clin Pract Gastroenterol Hepatol 6(2): 68-9.
Fontana, R. J. and H. L. Bonkovsky, et al. (2009). "Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis." Clin Gastroenterol Hepatol 7(2): 219-26.
Degertekin, B. and M. Hussain, et al. (2009). "Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance." J Hepatol 50(1): 42-8.
Lok, A. S. and L. B. Seeff, et al. (2009). "Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease." Gastroenterology 136(1): 138-48.
Degertekin, B. and A. S. Lok (2008). "Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: which method should be used?" J Hepatol 48(6): 892-4.
Shetty, K. and M. Hussain, et al. (2008). "Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C." Liver Transpl 14(4): 534-40.
Lindsay, K. L. and C. Morishima, et al. (2008). "Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C." Clin Gastroenterol Hepatol 6(2): 234-41.
Tan, J. and B. Degertekin, et al. (2008). "Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations." J Hepatol 48(3): 391-8.
Seeff, L. B. and T. M. Curto, et al. (2008). "Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial." Hepatology 47(2): 605-12.
Di Bisceglie, A. M. and M. L. Shiffman, et al. (2008). "Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon." N Engl J Med 359(23): 2429-41.
Degertekin, B. and A. S. Lok (2008). "Should liver biopsies be performed on all hepatitis B carriers?" Gastroenterology 135(5): 1802; author reply 1802-3.
Lok, A. S. (2008). "How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting." Liver Transpl 14 Suppl 2: S8-S14.
Gaglio, P. and S. Singh, et al. (2008). "Impact of the hepatitis B virus genotype on pre- and post-liver transplantation outcomes." Liver Transpl 14(10): 1420-7.
Morishima, C. and T. R. Morgan, et al. (2008). "Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C." Hepatology 48(5): 1412-9.
Fontana, R. J. and Z. Kronfol, et al. (2008). "Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C." Am J Gastroenterol 103(11): 2766-75.
Gish, R. G. and A. S. Lok, et al. (2007). "Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B." Gastroenterology 133(5): 1437-44.
Osborn, M. K. and S. H. Han, et al. (2007). "Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list." Clin Gastroenterol Hepatol 5(12): 1454-61.
Degertekin, B. and A. S. Lok (2007). "When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection?" Ann Intern Med 147(1): 62-4.
Bieliauskas, L. A. and C. Back-Madruga, et al. (2007). "Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C." J Int Neuropsychol Soc 13(4): 687-92.
Fontana, R. J. and L. A. Bieliauskas, et al. (2007). "Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C." Hepatology 45(5): 1154-63.
Sharma, P. and J. A. Marrero, et al. (2007). "Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence." Liver Transpl 13(8): 1100-8.
Hoofnagle, J. H. and E. Doo, et al. (2007). "Management of hepatitis B: summary of a clinical research workshop." Hepatology 45(4): 1056-75.
Tan, J. and A. S. Lok (2007). "Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B." Liver Transpl 13(3): 323-6.
Wong, S. N. and C. J. Chu, et al. (2007). "Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy." Liver Transpl 13(3): 374-81.
Lok, A. S. and J. E. Everhart, et al. (2007). "Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial." Clin Gastroenterol Hepatol 5(2): 245-54.
Lok, A. S. and B. J. McMahon (2007). "Chronic hepatitis B." Hepatology 45(2): 507-39.
Shiffman, M. L. and M. G. Ghany, et al. (2007). "Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C." Gastroenterology 132(1): 103-12.
Terrault, N. A. and M. L. Shiffman, et al. (2007). "Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation." Liver Transpl 13(1): 122-9.
Liu, Y. and M. Hussain, et al. (2007). "A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA." J Clin Microbiol 45(2): 553-8.
Wong, S. N. and K. R. Reddy, et al. (2007). "Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma." Liver Transpl 13(3): 334-42.
Wong, S. N. and A. S. Lok (2006). "Update on viral hepatitis: 2005." Curr Opin Gastroenterol 22(3): 241-7.
Lai, C. L. and D. Shouval, et al. (2006). "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B." N Engl J Med 354(10): 1011-20.
Chang, T. T. and R. G. Gish, et al. (2006). "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B." N Engl J Med 354(10): 1001-10.
Wong, S. N. and A. S. Lok (2006). "Treatment of hepatitis B: who, when, and how?" Arch Intern Med 166(1): 9-12.
Fung, S. K. and H. B. Chae, et al. (2006). "Virologic response and resistance to adefovir in patients with chronic hepatitis B." J Hepatol 44(2): 283-90.
Everson, G. T. and J. C. Hoefs, et al. (2006). "Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial." Hepatology 44(6): 1675-84.
Bieliauskas, L. A. and C. Back-Madruga, et al. (2006). "Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosis." J Clin Exp Neuropsychol 28(8): 1346-61.
Yim, H. J. and M. Hussain, et al. (2006). "Evolution of multi-drug resistant hepatitis B virus during sequential therapy." Hepatology 44(3): 703-12.
Fung, S. K. and F. S. Wong, et al. (2006). "Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center." Liver Int 26(7): 796-804.
Kang, H. and A. S. Lok (2006). "Endpoints for clinical trials on treatment of hepatitis C." J Hepatol 45(4): 473-5.
Morishima, C. and T. R. Morgan, et al. (2006). "HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial." Hepatology 44(2): 360-7.
Wong, S. N. and A. S. Lok (2006). "Tenofovir disoproxil fumarate: role in hepatitis B treatment." Hepatology 44(2): 309-13.
Osborn, M. K. and A. S. Lok (2006). "Antiviral options for the treatment of chronic hepatitis B." J Antimicrob Chemother 57(6): 1030-4.
Fontana, R. J. and L. A. Bieliauskas, et al. (2005). "Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial." J Hepatol 43(4): 614-22.
Fung, S. K. and P. Andreone, et al. (2005). "Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation." J Hepatol 43(6): 937-43.
Di Bisceglie, A. M. and R. K. Sterling, et al. (2005). "Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial." J Hepatol 43(3): 434-41.
Lok, A. S. and M. G. Ghany, et al. (2005). "Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort." Hepatology 42(2): 282-92.
Fung, S. K. and A. S. Lok (2005). "Update on viral hepatitis in 2004." Curr Opin Gastroenterol 21(3): 300-7.
Fung, S. K. and A. S. Lok (2005). "Management of patients with hepatitis B virus-induced cirrhosis." J Hepatol 42 Suppl(1): S54-64.
Fung, S. K. and A. S. Lok (2004). "Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B." Nat Clin Pract Gastroenterol Hepatol 1(2): 90-7.
Fung, S. K. and A. S. Lok (2004). "Viral hepatitis in 2003." Curr Opin Gastroenterol 20(3): 241-7.
Fung, S. K. and A. S. Lok (2004). "Management of hepatitis B patients with antiviral resistance." Antivir Ther 9(6): 1013-26.
Lok, A. S. (2004). "Prevention of hepatitis B virus-related hepatocellular carcinoma." Gastroenterology 127(5 Suppl 1): S303-9.
Fung, S. K. and A. S. Lok (2004). "Treatment of chronic hepatitis B: who to treat, what to use, and for how long?" Clin Gastroenterol Hepatol 2(10): 839-48.
Lee, W. M. and J. L. Dienstag, et al. (2004). "Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders." Control Clin Trials 25(5): 472-92.
Fung, S. K. and A. S. Lok (2004). "Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?" Hepatology 40(4): 790-2.
Lok, A. S. and B. J. McMahon (2004). "[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines]." Rom J Gastroenterol 13(2): 150-4.
Lok, A. S. (2004). "New treatment of chronic hepatitis B." Semin Liver Dis 24 Suppl 1: 77-82.
Shehab, T. M. and R. J. Fontana, et al. (2004). "Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice." Clin Gastroenterol Hepatol 2(5): 425-31.
Shiffman, M. L. and A. M. Di Bisceglie, et al. (2004). "Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment." Gastroenterology 126(4): 1015-23; discussion 947.
Lok, A. S. and B. J. McMahon (2004). "Chronic hepatitis B: update of recommendations." Hepatology 39(3): 857-61.
Marrero, J. A. and A. S. Lok (2004). "Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit?" Gastroenterology 126(1): 347-50.
Shehab, T. M. and M. Orrego, et al. (2003). "Identification and management of hepatitis C patients in primary care clinics." Am J Gastroenterol 98(3): 639-44.
Lok, A. S. (2003). "Hepatitis B: progress in the last decade." Semin Liver Dis 23(1): 1-4.
Lok, A. S. and C. L. Lai, et al. (2003). "Long-term safety of lamivudine treatment in patients with chronic hepatitis B." Gastroenterology 125(6): 1714-22.
Huang, M. A. and A. S. Lok (2003). "Natural history of hepatitis B and outcomes after liver transplantation." Clin Liver Dis 7(3): 521-36.
Di Bisceglie, A. M. and A. C. Lyra, et al. (2003). "Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status." Am J Gastroenterol 98(9): 2060-3.
Hussain, M. and C. J. Chu, et al. (2003). "Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants." J Clin Microbiol 41(8): 3699-705.
Chu, C. J. and E. B. Keeffe, et al. (2003). "Hepatitis B virus genotypes in the United States: results of a nationwide study." Gastroenterology 125(2): 444-51.
Wai, C. T. and C. J. Chu, et al. (2002). "HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C." Hepatology 36(6): 1425-30.
Chu, C. J. and M. Hussain, et al. (2002). "Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection." Hepatology 36(6): 1408-15.
Wai, C. T. and A. S. Lok (2002). "Treatment of hepatitis B." J Gastroenterol 37(10): 771-8.
Fontana, R. J. and A. S. Lok (2002). "Noninvasive monitoring of patients with chronic hepatitis C." Hepatology 36(5 Suppl 1): S57-64.
Lok, A. S. (2002). "Prevention of recurrent hepatitis B post-liver transplantation." Liver Transpl 8(10 Suppl 1): S67-73.
Lok, A. S. and F. Zoulim, et al. (2002). "Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay." J Clin Microbiol 40(10): 3729-34.
Fontana, R. J. and S. M. Schwartz, et al. (2002). "Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C." Psychosomatics 43(5): 378-85.
Chu, C. J. and M. Hussain, et al. (2002). "Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C." Gastroenterology 122(7): 1756-62.
Lok, A. S. (2002). "Chronic hepatitis B." N Engl J Med 346(22): 1682-3.
Fontana, R. J. and E. B. Keeffe, et al. (2002). "Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B." Liver Transpl 8(5): 433-9.
Chu, C. J. and A. S. Lok (2002). "Clinical significance of hepatitis B virus genotypes." Hepatology 35(5): 1274-6.
Fontana, R. J. and K. B. Hussain, et al. (2002). "Emotional distress in chronic hepatitis C patients not receiving antiviral therapy." J Hepatol 36(3): 401-7.